The proportion of individuals with hSBA titers ≥ 1 4 among subjects vaccinated with the bivalent rLP2086 vaccine ranged from 75%to100%0% against MnB strains with fHBP variants common to both IMBD and meningococcal carriage isolates.
To compare the relative efficacy of DNA vaccines delivered IM by needle and syringe versus the needle-free Agro-Jet® device injection, a dose-response study was performed with amounts of DNA vaccine ranging from 500 to 0.5 µg with two inoculations.
In five of these studies clinically significant efficacy was demonstrated against circulating H1N1 strains matched to the vaccine (ranging from 81% to 100%) while in the sixth study A/H1N1 strains did not circulate in the community which precluded an estimate of efficacy.
The ICER for the quadrivalent vaccine ranged from €1,000 to €73,100 per QALY gained.
The vaccine ranges used were Nobivac from Intervet, Purevax from Merial and Virbagen felis from Virbac (in alphabetical order).
In the univariate sensitivity analyses, the ICER for the bivalent HPV vaccine ranged from €2,200 to €97,100 per QALY gained.
It is involved in the entire gamut of operations to develop and test a vaccine – ranging from basic laboratory research to clinical tests.
The estimates for the absolute efficacy (VE SP) of live vaccine ranged from 28%9595% CI: −67, 67) to 57% (95% CI: −3, 82).
The number of subjects in Phase III trials for a vaccine ranged from 2,358 (IPOL) to 80,427 (Rotarix), with mean = 29,844 and median = 22,938.
The total number of subjects in late phase (II + III) trials for a vaccine ranged from 2,719 (IPOL) to 86,801 (Rotarix), with mean = 32,698 and median = 26,985.
